Vonvendi FDA Approval History
FDA Approved: Yes (First approved December 8, 2015)
Brand name: Vonvendi
Generic name: von willebrand factor (recombinant)
Dosage form: for Injection
Company: Baxalta Incorporated
Treatment for: von Willebrand Disease
Vonvendi [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor (VWF) indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease.
Development Timeline for Vonvendi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.